



## **ANADYS PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR END 2009 FINANCIAL RESULTS**

**San Diego, February 17, 2010** – Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report fourth quarter and year end 2009 financial results on Wednesday, February 24, 2010, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Wednesday, February 24, 2010 at 5:00 p.m. Eastern Standard Time to discuss its fourth quarter and year end 2009 financial results and to provide an update on the ANA598 development program, including a presentation of 12 week safety and antiviral response data for the 200 mg bid cohort in the ongoing Phase II combination trial. A live webcast of the call will be available online at [www.anadyspharma.com](http://www.anadyspharma.com). A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 92658014. The webcast and telephone replay will be available through March 10, 2010.

### **About Anadys**

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

### **Safe Harbor Statement**

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended September 30, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

###

**Investor Contact:**

Amy Conrad  
Anadys Pharmaceuticals, Inc.  
(858) 530-3607  
[aconrad@anadyspharma.com](mailto:aconrad@anadyspharma.com)

**Media Contact:**

Ian Stone or David Schull  
Russo Partners, LLC  
(619) 528-2220  
[ian.stone@russopartnersllc.com](mailto:ian.stone@russopartnersllc.com)  
[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)